Elicio Therapeutics financials
$1.84−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$37.7M | -$45.0M | -$35.7M |
| Net income | -$39.6M | -$51.9M | -$35.2M |
| Net margin | — | — | — |
| Diluted EPS | $-2.58 | $-4.25 | $-6.96 |
| EBITDA | -$37.5M | -$44.7M | -$35.4M |
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M |
| Diluted shares | 15.3M | 12.2M | 5.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $18.6M | $17.6M | $12.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $9.4M | $20.0M | $0.00 |
| Total assets | $25.9M | $28.2M | $27.1M |
| Total liabilities | $24.2M | $39.5M | $15.8M |
| Shareholders' equity | $1.6M | -$11.3M | $11.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology